Currently, the majority of ovarian cancers – upwards of 75 percent – are of the subtype “high grade serous carcinoma,” which is the type being treated in this phase 2 study.
Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC
The new CCTG Strategic Plan: Solving Cancer Together articulates the scientific priorities and required supporting activities that would lead the Group through to 2027. Our new scientific priorities: Understand Cancer Biology, Reduce the Cancer Burden, and Improve Cancer Care with their associated objectives and activities will lead to new advances in innovative therapies, understanding resistance, reduce the burdens of cancer, and show the value of these innovations.
A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.
Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.
The CCTG New Investigator Clinical Trials Course is fast approaching and has already reached the maximum registration. The course will be held August 3 – 5, 2022 in Kingston, Ontario to provide and facilitate investigator education and training designed to educate new investigators from across the country about the essentials of clinical trial conduct in the Canadian research environment.
It was recently announced that ExCELLirate Canada has successfully been granted a Research Infrastructure award of $4,159,049 by the Ontario Research Fund for the Innovation Fund Project Grant "ExCELLirate Canada: Expanding CELL-based Immunotherapy Research Acceleration for Translation and Evaluation".
CCTG trials that were featured at the American Society of Clinical Oncology General Meeting 2022 June 3-7, 2022 – McCormick Place, Chicago
The findings of the CCTG MA32 trial were published recently in the Journal of the American Me
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
Late Recurrence Substudy of A Phase III Randomized Trial of Metformin vs Placebo on Recurrence and Surivival in Early-Stage Breast Cancer
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
Value In Health 25: 1157 - 1164, 2022Everest L;Blommaert S;Tu D;Pater JL;Hay A;Cheung MC;Chan KKW;
Nature Communications 13: 3607 - 3619, 2022Hilton J;Gelmon K;Bedard PL;Tu D;Xu H;Tinker AV;Goodwin R;Laurie SA;Jonker D;Hansen AR;Veitch ZW;Renouf DJ;Hagerman L;Lui H;Chen B;Kellar D;Li I;Lee SE;Kono T;Cheng BYC;Yap D;Lai D;Beatty S;Soong J;Pritchard KI;Soria-Bretones I;Chen E;Feilotter H;Rushton M;Seymour L;Aparicio S;Cescon DW;
J Clin Oncol 40: 9046 - 9046, 2022Parra ER;Duose DY;Zhang J;Redman MW;Lazcano Segura R;Marques-Piubelli ML;Laberiano Fernandez C;Zhang B;Lindsay J;Moravec R;Kannan K;Luthra R;Alatrash G;Herbst RS;Wistuba II;Gettinger SN;Bazhenova L;Lee JJ;Zhang J;Haymaker CL;
J Clin Oncol 40: 9044 - 9044, 2022Gonzalez-Kozlova E;Huang HH;Redman MW;Herbst RS;Gettinger SN;Bazhenova L;Xie H;Patel M;Nie K;Harris J;Argueta K;Cerami E;Hong J;Biswas R;Van Nostrand S;Kelly K;Moravec R;Del Valle D;Kim-Schulze S;Gnjatic S;
J Clin Oncol 40: 6543 - 6543, 2022Vaidya R;Unger JM;Qian L;Minichiello K;Herbst RS;Gandara DR;Neal JW;Leal T;Patel JD;Dragnev KH;Waqar SN;Edelman MJ;Sigal EV;Adam S;Malik SM;Blanke CD;LeBlanc ML;Kelly K;Redman MW;
J Clin Oncol 40: 9067 - 9067, 2022Leitzel K;Ali SM;Ding K;Leighl NB;Vera Badillo FE;Gaudreau PO;Bradbury PA;Goss GD;Shepherd LE;Costa L;Suva LJ;Drabick JJ;Ma PC;Joshi M;Polimera HV;Lipton A;
J Clin Oncol 40: TPS4607 - TPS4607, 2022Gupta S;Ballman KV;Galsky MD;Morris MJ;Chen RC;Chan TA;Dercle L;Wen Y;Sridhar SS;Yen AE;Grivas P;Tan A;Baghaie S;Rosenberg JE;
